Drug intelligence / Profile preview

Velgraft

Development stage: Phase 1
Lead developer: Ayu
Modality: Stem Cell Therapies → Cell Therapies
Administration: Topical

Overview

**Velgraft** is a living allogeneic cellular skin substitute for chronic, non-infected wounds. It comprises a biodegradable polymeric chitosan-gelatin scaffold seeded with human bone-marrow-derived mesenchymal stem cells and mesenchymal-stem-cell-derived adipocytes. The product is applied as a wound graft/dressing and is intended to provide a temporary extracellular matrix-like scaffold, support host-cell migration, and deliver cell-derived growth factors and cytokines that may promote angiogenesis, tissue remodeling, and wound repair. Velgraft is being evaluated in a Phase 1 randomized controlled study for chronic diabetic foot ulcers with granulation tissue. ([ayulifescience.com](https://ayulifescience.com/advanced-wound-care/velgraft.html))

Brand names: Velgraft

Beyond the preview

Go deeper on Velgraft.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Velgraft.

Explore the full profile